Navigation Links
Recipient of Melanoma Drug in Development Celebrates Two Cancer-Free Years
Date:10/16/2007

KNOXVILLE, Tenn., Oct. 16 /PRNewswire/ -- When eighty-six-year-old Keith Hora went to see Dr. Peter Hersey, a medical oncologist and professor at the University of Newcastle in Australia, he was told he only had three to six months to live. Hora had been diagnosed with stage III melanoma, one of the most difficult to treat forms of cancer.

"Mr. Hora had multiple melanoma reoccurrences in the previously treated area of his face and nothing was helping him, including multiple surgeries to remove the tumors as well as radiation therapy," recalls Dr. Hersey, a fifteen-year member of the World Health Organization's committee on Melanoma. "His tumors kept returning."

Hora was included in a Phase 1 clinical trial of PV-10 conducted by Dr. Hersey. The trials were sponsored by Knoxville, TN-based Provectus Pharmaceuticals. PV-10 is a small molecule oncology agent being investigated by Provectus for treatment of melanoma and other focal forms of cancer.

"When it is injected into tumor tissue, the drug concentrates in the tumor at cytotoxic levels while quickly dissipating from healthy tissue," says Dr. Hersey. "This makes it safer and more effective than some other therapies."

Hora was treated in late 2005 and recalled getting the good news a few weeks later during an ultrasound follow-up that determined the tumors were shrinking. "After being cancer-free for two years, I feel like jumping over a moon," says Hora.

Provectus has begun the next round of testing intended to demonstrate definitively the efficacy of PV-10. The Phase 2 trial will treat up to eighty Stage III/IV melanoma patients at seven or more sites in Australia and the U.S. While PV-10 is currently undergoing clinical trials to treat melanoma and breast cancer, in pre-clinical testing the drug has been shown to kill many other types of cancer. Additional clinical testing for treatment of primary and metastatic liver cancers is expected to begin later this year or early in 200
'/>"/>

SOURCE Provectus Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
2. IDM Pharma Presents Preliminary Results from Phase II UVIDEM Melanoma Vaccine Clinical Trial
3. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
4. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
7. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
8. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
9. Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published
10. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
11. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... NORWALK, Conn. , Aug. 27, 2014  UBM ... , a leading online community for medical imaging professionals, ... Association for Medical Imaging Management,s 2014 Annual Meeting ... the conference coverage: , 11 Principles ... management can lead to greater profitability. , ...
(Date:8/27/2014)... , Aug. 27, 2014 /PRNewswire-iReach/ -- Emergency ... design, blended emergency medical training and response technologies, ... defibrillator) training from the Department of Homeland ... Reserve 81 st Regional Support Command ... contract includes nationwide CPR/AED/First Aid training. The Army ...
(Date:8/27/2014)... , Aug. 27, 2014   Auxilium Pharmaceuticals , Inc. ... biopharmaceutical company, today announced that certain members of the ... Healthcare Conference to be held September 8-10, 2014 in ... , Chief Executive Officer and President, is scheduled to ... portfolio at 10:55 a.m. ET on Wednesday, September 10, ...
Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Morgan Stanley Healthcare Conference 3
... Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in ... it has dosed the first patient with recent onset ... ongoing Phase I study of QPI-1007, the Company,s proprietary ... The Phase I open-label, dose-escalation study was initiated ...
... PHILADELPHIA, Oct. 20 ERT (Nasdaq: ... for the third quarter 2010 on Thursday, November 4, 2010, ... host a conference call at 5:00 PM EDT that day. ... dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 ...
Cached Medicine Technology:Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 2Quark Pharmaceuticals Doses First Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Patient in Stratum II of its Clinical Study of siRNA Drug Candidate QPI-1007 3ERT to Announce Third Quarter 2010 Results on November 4, 2010 2
(Date:8/27/2014)... Will Holbrook, CP LP, has joined ... over 15 years of experience in the prosthetics field. ... with a Bachelor of Science degree with a major ... received his graduate degree in prosthetics at Northwestern University ... Will join us at Fourroux,” says Keith Watson, owner ...
(Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... Albany, New York (PRWEB) August 27, 2014 ... published by Transparency Market Research "Ablation Technologies Market ... Technologies: Radiofrequency, Light/Laser, Electrical, Ultrasound, Microwave, Cryotherapy) - ... Forecast, 2014 - 2020," the global ablation technologies ... 2013 and is estimated to reach a market ...
(Date:8/27/2014)... Center for Leadership in Disability (CLD) has received ... Child Health Bureau of the Health Resources and ... Plan for Georgia, aimed at improving services for ... In preparing for this project, CLD worked with ... from across Georgia. The resulting plan addresses priorities ...
Breaking Medicine News(10 mins):Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 2Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 3Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 4Health News:Global Ablation Technologies Market Expected to Reach USD 10.6 Billion in 2020: Transparency Market Research 5
... in the last one month in Deomali and its ... officer N Singh said today. // ,Singh ... war footing to bring the situation under control., ... claimed death of 20 people in 15 days and ...
... of Georgia say that even if the surgery has gone ... of cardiovascular disease// and possibly cancer for several weeks post-operatively. ... is that when bad things happen down the road, months, ... in the past, just attribute it to the natural course ...
... today said it has entered into an agreement with ... of Foot and Mouth Disease (FMD) vaccine developed by ... the agreement, we will produce and market the vaccine ... meet the requirements of the domestic market and if ...
... 6. Even as asthma patients from different parts of ... fish medicine, rationalists have stepped up their campaign against ... of rationalists, has again urged the Andhra Pradesh government ... 'drug' was based on 'superstition'. ,The Bathini family, ...
... activity of a protein called NFATc1 tends to cause ... treat osteoporosis //- HHMI investigator Gerald Crabtree and HHMI ... bone is constantly being formed and being broken down ... cells called osteoblasts replenish it. ,‘Ideally, ...
... illness, which was under-diagnosed till now was found to ... thought before//. Intermittent Explosive Disorder or Rage disorder is ... outbursts. This illness if left untreated may also lead ... ,Intermittent Explosive Disorder attacks are out of proportion to ...
Cached Medicine News:Health News:Well-Planned Surgeries Also Carry Health Risks 2Health News:Well-Planned Surgeries Also Carry Health Risks 3Health News:'Fishy' Medicine Stirs Controversy 2Health News:'Fishy' Medicine Stirs Controversy 3Health News:Osteoporosis – A New Treatmen 2Health News:Osteoporosis – A New Treatmen 3Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 2Health News:Intermittent Explosive Disorder is More Prevalent Now Than Before 3
... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: